Mark Leiser

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Patients with multiple myeloma often become refractory to first-line triplet or quadruplet therapy regimens, creating a need for effective second- or later-line treatments.

Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.The award recognizes van ’t Veer for her work advancing risk stratification, subtyping and improved treatment for early breast cancer.

The FDA approved inavolisib as part of combination therapy for certain adults with breast cancer.The indication applies to use of inavolisib (Itovebi, Genentech) with palbociclib (Ibrance, Pfizer) and fulvestrant for treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer whose disease recurred on or after adjuvant endocrine

Cincinnati Children’s has retained its distinction as the No. 1 children’s hospital for cancer in the country.The institution tops U.S. News & World Report’s list of best hospitals for pediatric cancer for 2024-2025.

PROVIDENCE, Rhode Island — The influence digital opinion leaders have on health care stakeholders and patients will continue to grow as new opportunities for education and collaboration arise, according to a presenter at the COSMO Meeting.“Digital opinion leaders will continue to serve as a vital resource in public and medical communities,” Eleonora Teplinsky, MD, head of breast

PROVIDENCE, Rhode Island — Physicians and other health care professionals can utilize social media to support diversity, equity and inclusion in cancer care, according to a presenter at the COSMO Meeting.These strategies can improve patient care, diversify the oncology workforce and expand research.

PROVIDENCE, Rhode Island — Misinformation about cancer is prevalent on social media, spanning across platforms and malignancy types, according to a presenter at the COSMO Meeting.“Marginalization and distrust in the health care system may drive patients and families to misinformation exposure through alternative online sources,” Stacy Loeb, MD, MSc, PhD(Hon), professor of

Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.The OS benefit appeared generally consistent across subgroups, including those based on PD-L1 status and nodal expression, findings presented at ESMO Congress

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the United States.

Cognition appeared associated with likelihood that individuals would return to work 2 years after breast cancer diagnosis, according to results of a case series study.Prior research showed at least half of patients with breast cancer report cognitive challenges — such as such as difficulties with attention, memory or processing speed — after adjuvant chemotherapy, according to study

The social media revolution in oncology is well under way.The transformation will only accelerate as physicians, advanced practice providers, industry representatives, patient advocates and others seek new ways to communicate, educate themselves and expand their networks.

11 Jul 2024 ... The leading risk factor — cigarette smoking — contributed to nearly one in five cancer cases and nearly three in 10 cancer deaths, findings ...

Ethan Basch, MD, MSc, FASCO, will receive the Joseph Simone Quality Care Award and Lecture at this year’s ASCO Quality Care Symposium, scheduled for Sept. 27-28.The award recognizes significant and enduring contributions to the quality and safety of cancer care.

CHICAGO — The addition of abemaciclib to fulvestrant extended PFS for patients with advanced breast cancer whose disease progressed on prior cyclin-dependent kinase 4/6 inhibitor therapy, according to data presented at ASCO Annual Meeting.A combination of CDK 4/6 inhibitors and endocrine therapy is standard first-line therapy for patients with hormone receptor-positive, HER2-negative

Jeffrey M. Farma, MD, FACS, has been appointed chair of surgery at Fox Chase Cancer Center.Farma will oversee all departmental educational activities — including professional, student, residency and fellowship programs. He also will oversee mentoring and organizing the department’s clinical faculty.

Jonathan T. Yang, MD, PhD, has been appointed associate vice chair for clinical research and developmental therapeutics in the department of radiation oncology at NYU Langone Health’s Perlmutter Cancer Center.Yang also will serve as director of the metastatic disease service in the department of radiation oncology, as well as director of clinical research at the Brain and Spine Tumor

CHICAGO — The microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease, according to findings presented at ASCO Annual Meeting.Early-onset tumors appeared enriched for several microbial genera associated with pancreatic diseases, a finding researchers called “significant” and worthy of additional study.

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The analysis — which included patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after endocrine therapy — also showed considerably

CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.Women who used estrogen-only hormone therapy exhibited increased risk for ovarian cancer incidence and mortality, findings presented during a pre-ASCO press conference showed.

The FDA granted accelerated approval to tarlatamab-dlle for treatment of certain patients with extensive-stage small cell lung cancer.The indication applies to use of the agent by patients whose disease progressed on or after platinum-based chemotherapy.